Author Archives: Alice Melão, MSc

Plans for Phase 2 Trial of Brilaroxazine in IPF Patients Moving Ahead, Reviva Says

Plans for a Phase 2 clinical trial of brilaroxazine, the lead candidate by Reviva Pharmaceuticals to treat idiopathic pulmonary fibrosis (IPF), were the focus of a recent and successful meeting between company officials and the U.S. Food and Drug Administration (FDA), Reviva announced. During this pre-Investigational New Drug (IND) Application meeting, the regulatory…

Frailty Assessment May Help Identify IPF Patients at Risk, Study Says

Frailty and geriatric conditions, such as incontinence, dizziness, vision impairment, hearing impairment, and falls, are common among older patients with idiopathic pulmonary fibrosis (IPF), a pilot study finds. Recognition of such commonly associated age-related complications may help identify IPF patients at risk of a poorer outcome, researchers suggest. The study,…